Your browser doesn't support javascript.
loading
Nucleolin Targeting by N6L Inhibits Wnt/ß-Catenin Pathway Activation in Pancreatic Ductal Adenocarcinoma.
Raineri, Fabio; Bourgoin-Voillard, Sandrine; Cossutta, Mélissande; Habert, Damien; Ponzo, Matteo; Houppe, Claire; Vallée, Benoît; Boniotto, Michele; Chalabi-Dchar, Mounira; Bouvet, Philippe; Couvelard, Anne; Cros, Jerome; Debesset, Anais; Cohen, José L; Courty, José; Cascone, Ilaria.
Affiliation
  • Raineri F; University Paris Est Créteil, INSERM, IMRB, 94010 Créteil, France.
  • Bourgoin-Voillard S; University Paris Est Créteil, INSERM, IMRB, 94010 Créteil, France.
  • Cossutta M; University of Grenoble Alpes, CNRS, Grenoble INP, Inserm U1055, LBFA and BEeSy, PROMETHEE Proteomic Platform, 38400 Saint-Martin d'Heres, France.
  • Habert D; University of Grenoble Alpes, CNRS, Grenoble INP, TIMC, PROMETHEE Proteomic Platform, 38000 Grenoble, France.
  • Ponzo M; CHU Grenoble Alpes, Institut de Biologie et de Pathologie, 38043 Grenoble, France.
  • Houppe C; University Paris Est Créteil, INSERM, IMRB, 94010 Créteil, France.
  • Vallée B; AP-HP, Groupe Hospitalo-Universitaire Chenevier Mondor, Centre d'Investigation Clinique Biotherapie, 94010 Créteil, France.
  • Boniotto M; University Paris Est Créteil, INSERM, IMRB, 94010 Créteil, France.
  • Chalabi-Dchar M; University Paris Est Créteil, INSERM, IMRB, 94010 Créteil, France.
  • Bouvet P; University Paris Est Créteil, INSERM, IMRB, 94010 Créteil, France.
  • Couvelard A; University Paris Est Créteil, INSERM, IMRB, 94010 Créteil, France.
  • Cros J; University Paris Est Créteil, INSERM, IMRB, 94010 Créteil, France.
  • Debesset A; Centre de Recherche en Cancérologie de Lyon, Cancer Cell Plasticity Department, University of Lyon, UMR INSERM 1052 CNRS 5286, Centre Léon Bérard, 69008 Lyon, France.
  • Cohen JL; Centre de Recherche en Cancérologie de Lyon, Cancer Cell Plasticity Department, University of Lyon, UMR INSERM 1052 CNRS 5286, Centre Léon Bérard, 69008 Lyon, France.
  • Courty J; University of Lyon, Ecole Normale Supérieure de Lyon, 69342 Lyon, France.
  • Cascone I; Département de Pathologie, Hôpital Bichat APHP DHU UNITY, 75018 Paris, France.
Cancers (Basel) ; 13(12)2021 Jun 15.
Article in En | MEDLINE | ID: mdl-34203710
ABSTRACT
Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive and resistant cancer with no available effective therapy. We have previously demonstrated that nucleolin targeting by N6L impairs tumor growth and normalizes tumor vessels in PDAC mouse models. Here, we investigated new pathways that are regulated by nucleolin in PDAC. We found that N6L and nucleolin interact with ß-catenin. We found that the Wnt/ß-catenin pathway is activated in PDAC and is necessary for tumor-derived 3D growth. N6L and nucleolin loss of function induced by siRNA inhibited Wnt pathway activation by preventing ß-catenin stabilization in PDAC cells. N6L also inhibited the growth and the activation of the Wnt/ß-catenin pathway in vivo in mice and in 3D cultures derived from MIA PaCa2 tumors. On the other hand, nucleolin overexpression increased ß-catenin stabilization. In conclusion, in this study, we identified ß-catenin as a new nucleolin interactor and suggest that the Wnt/ß-catenin pathway could be a new target of the nucleolin antagonist N6L in PDAC.
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Cancers (Basel) Year: 2021 Document type: Article Affiliation country: France

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Cancers (Basel) Year: 2021 Document type: Article Affiliation country: France
...